Medullary thyroid carcinoma (MTC) responds very poorly to chemotherapy. Mutations in the RET gene are critical for MTC pathogenesis. RET therefore represents a rational target for the development of novel MTC therapies. The accumulation of evidence from laboratory studies strongly suggests that PP1 inhibitor is a cytostatic agent for cells expressing RET oncoproteins. PP1 functions as a potent and selective inhibitor of RET oncoprotein phosphorylation, promoting its proteasomal degradation.
|Titolo:||RETMEN2A and RETMEN2B oncoproteins are targets of PP1 inhibitor|
|Parole Chiave:||Medullary thyroid cancer pathogenesis; MEN 2A; MEN 2B; PP1 inhibitor; RET oncoproteins|
|Settore Scientifico Disciplinare:||Settore BIO/09 - Fisiologia|
|Data di pubblicazione:||set-2003|
|Appare nelle tipologie:||01 - Articolo su periodico|